A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

计划入组 66 人 · 首次发布于 2013 年 8 月 7 日

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

计划入组 80 人 · 首次发布于 2015 年 12 月 11 日

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

计划入组 19 人 · 首次发布于 2007 年 8 月 29 日

anti-HER-3 albubody Albumod (Affibody)

177-Lu-HER3-ARC

225-Ac-HER3-ARC

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Mattel Launches First Type 1 Diabetes Barbie Doll with Medical Device Accessories

Longview Passes Ordinance Criminalizing Child Exposure to Schedule I and II Controlled Substances

Akeso Reports Record Sales Growth as Ivonescimab Meets Overall Survival Endpoint in Phase III Trial